@article{11fb80b184834c2599cef34d4ee24d6a,
title = "COVID-19 Vaccine Reactogenicity and Vaccine Attitudes among Children and Parents/Guardians after Multisystem Inflammatory Syndrome in Children or COVID-19 Hospitalization: September 2021 - May 2022",
abstract = "Background: Multisystem inflammatory syndrome in children (MIS-C) is a multiorgan hyperinflammatory condition following SARS-CoV-2 infection. Data on COVID-19 vaccine adverse events and vaccine attitudes in children with prior MIS-C are limited. We described characteristics associated with COVID-19 vaccination, vaccine adverse events and vaccine attitudes in children with a history of MIS-C or COVID-19 and their parents/guardians. Methods: We enrolled children previously hospitalized for MIS-C or COVID-19 from 3 academic institutions. We abstracted charts and interviewed children and parents/guardians regarding vaccine adverse events and acceptability. Results: Of 163 vaccine-eligible children enrolled with a history of MIS-C and 70 with history of COVID-19, 51 (31%) and 34 (49%), respectively, received mRNA COVID-19 vaccine a median of 10 (Interquartile Range 6-13) months after hospital discharge. Among 20 children with MIS-C and parents/guardians who provided interviews, local injection site reaction of brief duration (mean 1.8 days) was most commonly reported; no children required medical care within 2 weeks postvaccination. Vaccine survey results of interviewed, vaccinated children and their parents/guardians: of 20 children with MIS-C and 15 children with COVID-19, 17 (85%) and 13 (87%), respectively, listed doctors in the top 3 most trusted sources for vaccine information; 13 (65%) and 9 (60%) discussed vaccination with their doctor. Conclusions: COVID-19 vaccination was well tolerated in children with prior MIS-C or COVID-19 participating in our investigation. Parents/guardians regarded their children's doctors as a trusted source of information for COVID-19 vaccines, and most vaccinated children's parents/guardians had discussed COVID-19 vaccination for their child with their doctor.",
keywords = "COVID-19, MIS-C, adverse events, vaccine",
author = "Yousaf, {Anna R.} and Amber Kunkel and Abrams, {Joseph Y.} and Shah, {Ami B.} and Hammett, {Teresa A.} and Arnold, {Kathryn E.} and Beltran, {Yajira L.} and Laham, {Federico R.} and Kao, {Carol M.} and Hunstad, {David A.} and Laila Hussaini and Nadine Baida and Luis Salazar and Perez, {Maria A.} and Rostad, {Christina A.} and Shana Godfred-Cato and Campbell, {Angela P.} and Belay, {Ermias D.}",
note = "Funding Information: F.R.L. received a grant from Lilly for work unrelated to this investigation. D.A.H. serves on the Board of Directors of BioVersys AG, Basel, Switzerland (work unrelated to this manuscript), and has received funding from BioAge Laboratories for research work unrelated to this manuscript. His institution has received NIH research funding to conduct Moderna COVID-19 vaccine clinical trials. C.A.R.{\textquoteright}s institution has received funding to conduct clinical research unrelated to this manuscript from BioFire Inc., GSK, MedImmune, Micron, Merck, Novavax, PaxVax, Regeneron, Pfizer and Sanofi-Pasteur. She is a coinventor of patented respiratory syncytial virus (RSV) vaccine technology unrelated to this manuscript, which has been licensed to Meissa Vaccines, Inc. Her institution has received funding from NIH to conduct clinical trials of Moderna and Janssen COVID-19 vaccines. All other authors have no conflicts of interest or funding to disclose. Funding Information: This investigation was supported by the Centers for Disease Control and Prevention (CDC). The CDC provided funds for the principal investigators and abstractors and laboratory sample collection and testing (contract #75D30120C09256). Publisher Copyright: {\textcopyright} 2023 Lippincott Williams and Wilkins. All rights reserved.",
year = "2023",
month = mar,
day = "1",
doi = "10.1097/INF.0000000000003803",
language = "English",
volume = "42",
pages = "252--259",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
number = "3",
}